CP-023 Use of intravitreal antiangiogenic drug in a large study in the treatment of retinopathy of prematurity

BackgroundRetinopathy of prematurity (ROP) is a proliferative disease of the retinal vasculature that can cause severe visual loss in premature newborns. Intravitreal bevacizumab has shown promise as a treatment for ROP.PurposeTo evaluate the efficacy and safety of intravitreal bevacizumab in preterm infants with retinopathy diagnosed with grades 1–3+.Material and methodsThis was a retrospective study of 24 months’ duration involving patients less than 30 weeks’ gestational age diagnosed with ROP to grade 3+ and weighing